ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2026)

ARS Pharmaceuticals' Assets Average history runs 6 years deep, the most recent figure standing at $307.6 million for Q1 2026.

• In Q1 2026, Assets Average fell 9.32% year-over-year to $307.6 million; the TTM figure through Mar 2026 stood at $307.6 million (down 9.32% YoY), while the FY2025 annual figure was $339.4 million, up 16.17% from the prior year.
• Assets Average came in at $307.6 million for Q1 2026 at ARS Pharmaceuticals, down from $350.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $350.2 million in Q4 2025 to a low of $187.0 million in Q1 2022.
• A 5-year average of $276.7 million and a median of $276.3 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 51.88% in 2022 and surged 56.13% in 2025, its largest moves.
• ARS Pharmaceuticals' Assets Average stood at $276.2 million in 2022, then declined by 12.81% to $240.9 million in 2023, then rose by 18.06% to $284.4 million in 2024, then grew by 23.16% to $350.2 million in 2025, then slipped by 12.17% to $307.6 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $307.6 million, $350.2 million, and $343.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison